A-779
(D-ALA7)-ANGIOTENSIN I/II (1-7)
CAS: 159432-28-7
Molecular Formula: C39H60N12O11
A-779 - Names and Identifiers
| Name | (D-ALA7)-ANGIOTENSIN I/II (1-7) |
| Synonyms | A-779 DRVYIHA A 779(3TFA) ASP-ARG-VAL-TYR-ILE-HIS-D-ALA H-ASP-ARG-VAL-TYR-ILE-HIS-D-ALA-OH |
| CAS | 159432-28-7 |
A-779 - Physico-chemical Properties
| Molecular Formula | C39H60N12O11 |
| Molar Mass | 872.97 |
| Density | 1.45±0.1 g/cm3(Predicted) |
| Appearance | lyophilized powder |
| Color | white to off-white |
| pKa | 3.29±0.10(Predicted) |
| Storage Condition | -15°C |
| In vitro study | A-779 inhibits the effect of Ang-(1-7), which suppresses the proliferating cell nuclear antigen (PCNA) protein expression up-regulated by Ang II, but A-779 alone has no effect to induce proliferation and migration of VSMCs. Pretreatment with Ang-(1-7) significantly retards Ang II-induced inflammatory responses of VSMCs associated with up-regulated MCP-1, VCAM-1 and IL-1β expressions, and this effect of Ang-(1-7) is blocked by A-779. But A-779 alone has no effect to induce inflammatory response of VSMCs. Pretreatment VSMCs with Ang-(1-7) for 5 min significantly inhibits Akt and ERK1/2 phosphorylation induced by Ang II, and this effect is also blocked by A-779, but alone has no effect to induce phosphorylation of Akt and ERK1/2 in VSMCs. |
| In vivo study | Infusion of Ang(1-7) and A-779 (400 ng/kg/min, s.c.) alone or combined for 6 weeks does not prevent uterus atrophy or inhibit the body weight gain of OVX rats. A-779 markedly elevates serum bone specific alkaline phosphatase (BALP), telopeptides of collagen type I (CTX), tartarate resistant acid phosphatase (TRAcP 5b), osteocalcin (OC) and urinary deoxypyridinoline (DPD). Infusion of Ang(1-7) and/or A-779 does not significantly change serum minerals concentrations in sham or OVX groups. A-779 in the OVX animals does not change AngII, Ang(1-7), AT1R, AT2R, ACE, ACE-2, Mas receptor, RANKL and OPG proteins expressions in relation to OVX group, while AngII (P [1] . Inhibition of Ang1-7 cascade by A-779 (400 ng/kg/min) significantly eradicates captopril protective effects on bone metabolism, mineralization and micro-structure. A-779 also restores OVX effects on RANKL expression and ACE-1/AngII/AT1R cascade and down-regulates OPG expression and ACE-2/Ang1-7/Mas pathway. |
A-779 - Preparation solution concentration reference
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 1.146 ml | 5.728 ml | 11.455 ml |
| 5 mM | 0.229 ml | 1.146 ml | 2.291 ml |
| 10 mM | 0.115 ml | 0.573 ml | 1.146 ml |
| 5 mM | 0.023 ml | 0.115 ml | 0.229 ml |
Last Update：2024-01-02 23:10:35
Supplier List
Spot supply
Product Name: (D-ALA7)-ANGIOTENSIN I/II (1-7) Visit Supplier Webpage Request for quotationCAS: 159432-28-7
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Spot supply
Product Name: (D-ALA7)-ANGIOTENSIN I/II (1-7) Visit Supplier Webpage Request for quotationCAS: 159432-28-7
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History